Subsequently, results of transwell assay and wound healing assay further confirmed the tumor-promoting properties of ANXA2P2 in HCC cells, and CCK8 assay demonstrated that ANXA2P2 has no impact on the proliferation of HCC cells, or when treated with targeted drugs, suggesting that ANXA2P2 may be a suitable predicative biomarker for risk assessment of recurrence or metastasis of HCC patients. This evidence concerns the gene ANXA2P2 and hepatocellular carcinoma.